{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:15:54Z","timestamp":1792080954412,"version":"4.4.0"},"reference-count":252,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inflammatory bowel disease (IBD) can affect extraintestinal organs, including the liver. The bidirectional relationship between the gut and liver underpins the interplay between IBD and liver pathologies; both are predicted to rise. This review discusses the anatomical-physiological context of the gut-liver axis, the influence of IBD on the liver and vice versa, and hepatobiliary conditions co-existing with IBD, namely, MASLD, ARLD, PSC and gallstones. About 70% of the liver\u2019s blood supply comes from the gut via the portal vein, which carries both nutrients and gut-derived microbial products, as regulated by the intestinal barrier. IBD is associated with gut dysbiosis and compromised intestinal barrier integrity (both exacerbated by alcohol consumption, an IBD risk factor), allowing microbial translocation to the liver, which triggers hepatic inflammation\/injury. This exacerbates pre-existing liver disease or increases its risk; for example, IBD increases MASLD risk. However, translocated lipopolysaccharides may alleviate cholestatic liver injury, enabling IBD to ameliorate PSC. In turn, PSC can promote a favourable gut microbiota profile to alleviate IBD. The liver maintains gut homeostasis\/microbiota through bile acid secretion. Disrupted bile acid secretion in gallstones increases IBD risk, while disrupted bile acid reabsorption in IBD increases gallstone risk. Disrupted bile acid metabolism and an abnormal gut microbiota in MASLD may exacerbate the IBD course. For co-existing IBD-hepatobiliary pathology, management strategies are unestablished, and adverse effects of IBD therapeutics on hepatobiliary pathologies are observed (and vice versa). This review facilitates a structured understanding of the pathophysiological connections and may inform\/improve the current management of coexisting IBD-hepatobiliary conditions.<\/jats:p>","DOI":"10.1007\/s10238-026-02102-w","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:42:05Z","timestamp":1775562125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0563-0208","authenticated-orcid":false,"given":"Ali","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6483-2254","authenticated-orcid":false,"given":"Ayan M.","family":"Sheikhnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4080-0461","authenticated-orcid":false,"given":"Kevin","family":"Ferrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6710-6223","authenticated-orcid":false,"given":"Lucy I.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-5081","authenticated-orcid":false,"given":"Kosha J.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2102_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573\u2013621. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101225.","journal-title":"Annu Rev Immunol"},{"key":"2102_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020305","volume":"13","author":"V Calvez","year":"2025","unstructured":"Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M, et al. Novel insights into the pathogenesis of inflammatory bowel diseases. Biomedicines. 2025;13:305. https:\/\/doi.org\/10.3390\/biomedicines13020305.","journal-title":"Biomedicines"},{"key":"2102_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238. https:\/\/doi.org\/10.1155\/2019\/7247238.","journal-title":"J Immunol Res"},{"key":"2102_CR4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","volume":"89","author":"JD Feuerstein","year":"2014","unstructured":"Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553\u201363. https:\/\/doi.org\/10.1016\/j.mayocp.2014.07.002.","journal-title":"Mayo Clin Proc"},{"key":"2102_CR5","unstructured":"Lynch WD, Hsu R. Ulcerative Colitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Feb 3]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459282\/. Accessed 3 Feb 2026."},{"key":"2102_CR6","unstructured":"Tian C, Ranasinghe IR, Hsu R. Crohn Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Feb 5]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK436021\/. Accessed 5 Feb 2026."},{"key":"2102_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-020-00280-5","volume":"15","author":"L Petagna","year":"2020","unstructured":"Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn\u2019s disease inflammation and recurrence. Biol Direct. 2020;15:23. https:\/\/doi.org\/10.1186\/s13062-020-00280-5.","journal-title":"Biol Direct"},{"key":"2102_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis,. Disease-a-Month. 2019;65:100851. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004.","journal-title":"Disease-a-Month"},{"key":"2102_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2468-1253(25)00263-8","volume":"11","author":"E Eggermont","year":"2026","unstructured":"Eggermont E, Gecse K, Krugliak Cleveland N, Petersen F, Sabino J, D\u2019Hoore A, et al. Ulcerative colitis: moving beyond the mucosal dogma. Lancet Gastroenterol Hepatol. 2026;11:163\u201374. https:\/\/doi.org\/10.1016\/S2468-1253(25)00263-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2102_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113690","volume":"14","author":"V Villanacci","year":"2025","unstructured":"Villanacci V, Maconi G, Laschi L, Bassotti G. Diagnosing ulcerative colitis: should we go beyond the surface? J Clin Med. 2025;14:3690. https:\/\/doi.org\/10.3390\/jcm14113690.","journal-title":"J Clin Med"},{"key":"2102_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, de Barreiro- Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv213.","journal-title":"J Crohns Colitis"},{"key":"2102_CR12","doi-asserted-by":"publisher","first-page":"7227","DOI":"10.3748\/wjg.v11.i46.7227","volume":"11","author":"S Danese","year":"2005","unstructured":"Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227\u201336. https:\/\/doi.org\/10.3748\/wjg.v11.i46.7227.","journal-title":"World J Gastroenterol"},{"key":"2102_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700\u201318. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.017.","journal-title":"Cell Metab"},{"key":"2102_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101859","volume":"71","author":"SG Rodrigues","year":"2024","unstructured":"Rodrigues SG, van der Merwe S, Krag A, Wiest R. Gut-liver axis: pathophysiological concepts and medical perspective in chronic liver diseases. Semin Immunol. 2024;71:101859. https:\/\/doi.org\/10.1016\/j.smim.2023.101859.","journal-title":"Semin Immunol"},{"key":"2102_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/diseases7040058","volume":"7","author":"H Fukui","year":"2019","unstructured":"Fukui H. Role of gut dysbiosis in liver diseases: what have we learned so far? Diseases. 2019;7:58. https:\/\/doi.org\/10.3390\/diseases7040058.","journal-title":"Diseases"},{"key":"2102_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.774335","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, et al. Gut microbiota targeted approach in the management of chronic liver diseases. Front Cell Infect Microbiol. 2022;12:774335. https:\/\/doi.org\/10.3389\/fcimb.2022.774335.","journal-title":"Front Cell Infect Microbiol"},{"key":"2102_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101475","volume":"12","author":"N Mendez-Sanchez","year":"2023","unstructured":"Mendez-Sanchez N, Coronel-Castillo CE, Cordova-Gallardo J, Qi X. Antibiotics in chronic liver disease and their effects on gut microbiota. Antibiotics. 2023;12:1475. https:\/\/doi.org\/10.3390\/antibiotics12101475.","journal-title":"Antibiotics"},{"key":"2102_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","volume":"19","author":"CD Fuchs","year":"2022","unstructured":"Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. 2022;19:432\u201350. https:\/\/doi.org\/10.1038\/s41575-021-00566-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2102_CR19","doi-asserted-by":"publisher","unstructured":"Singh S, Kriti M, Catanzaro R, Marotta F, Malvi M, Jain A, et al. Deciphering the gut\u2013liver axis: a comprehensive scientific review of non-alcoholic fatty liver disease. Livers. 2024;4:435\u201354. https:\/\/doi.org\/10.3390\/livers4030032.","DOI":"10.3390\/livers4030032"},{"key":"2102_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, Gottardi A, Rescigno M, Elsevier. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72:558\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.003.","journal-title":"J Hepatol"},{"key":"2102_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.799648","volume":"12","author":"LX Wang","year":"2021","unstructured":"Wang LX, Frey MR, Kohli R. The role of FGF19 and MALRD1 in enterohepatic bile acid signaling. Front Endocrinol (Lausanne). 2021;12:799648. https:\/\/doi.org\/10.3389\/fendo.2021.799648.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2102_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","volume":"215","author":"H Shapiro","year":"2018","unstructured":"Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med. 2018;215:383\u201396. https:\/\/doi.org\/10.1084\/jem.20171965.","journal-title":"J Exp Med"},{"key":"2102_CR23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.fmre.2024.09.007","volume":"5","author":"J Xu","year":"2025","unstructured":"Xu J, Chen N, Li Z, Liu Y. Gut microbiome and liver diseases. Fundam Res. 2025;5:890\u2013901. https:\/\/doi.org\/10.1016\/j.fmre.2024.09.007.","journal-title":"Fundam Res"},{"key":"2102_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.4254\/wjh.v13.i12.1956","volume":"13","author":"R Gaspar","year":"2021","unstructured":"Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: a review. World J Hepatol. 2021;13:1956\u201367. https:\/\/doi.org\/10.4254\/wjh.v13.i12.1956.","journal-title":"World J Hepatol"},{"key":"2102_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/ecco-jcc\/jjad157","volume":"18","author":"A Beheshti Maal","year":"2024","unstructured":"Beheshti Maal A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, Mansournia MA, Vosough M. Prevalence of hepatobiliary manifestations in inflammatory bowel disease: a GRADE assessed systematic review and meta-analysis of more than 1.7 million patients. J Crohns Colitis. 2024;18:360\u201374. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad157.","journal-title":"J Crohns Colitis"},{"key":"2102_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.4254\/wjh.v13.i11.1534","volume":"13","author":"G Losurdo","year":"2021","unstructured":"Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, et al. Liver involvement in inflammatory bowel disease: what should the clinician know? World J Hepatol. 2021;13:1534\u201351. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1534.","journal-title":"World J Hepatol"},{"key":"2102_CR27","doi-asserted-by":"publisher","unstructured":"Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z, et al. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Target Ther. 2025;10:33. https:\/\/doi.org\/10.1038\/s41392-024-02072-z.","DOI":"10.1038\/s41392-024-02072-z"},{"key":"2102_CR28","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1007\/s10620-024-08597-1","volume":"69","author":"Y Gong","year":"2024","unstructured":"Gong Y, He Y, Wan M, Chen H. Risk factors for gallstones in Crohn\u2019s disease: a systematic review and meta-analysis. Dig Dis Sci. 2024;69:4187\u2013202. https:\/\/doi.org\/10.1007\/s10620-024-08597-1.","journal-title":"Dig Dis Sci"},{"key":"2102_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","volume":"30","author":"K Lapumnuaypol","year":"2018","unstructured":"Lapumnuaypol K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:854\u201360. https:\/\/doi.org\/10.1097\/MEG.0000000000001144.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2102_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000199","volume":"23","author":"HK Bj\u00f6rnsson","year":"2024","unstructured":"Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Hepatotoxicity in inflammatory bowel disease: immunomodulators, biologics, and beyond. Clin Liver Dis. 2024;23:e0199. https:\/\/doi.org\/10.1097\/CLD.0000000000000199.","journal-title":"Clin Liver Dis"},{"key":"2102_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","volume":"22","author":"GG Kaplan","year":"2025","unstructured":"Kaplan GG. The global burden of inflammatory bowel disease: from 2025 to 2045. Nat Rev Gastroenterol Hepatol. 2025;22:708\u201320. https:\/\/doi.org\/10.1038\/s41575-025-01097-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2102_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020395","volume":"20","author":"I Milosevic","year":"2019","unstructured":"Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, et al. Gut-Liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci. 2019;20:395. https:\/\/doi.org\/10.3390\/ijms20020395.","journal-title":"Int J Mol Sci"},{"key":"2102_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrgastro.2017.79","volume":"14","author":"J Bernier-Latmani","year":"2017","unstructured":"Bernier-Latmani J, Petrova TV. Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat Rev Gastroenterol Hepatol. 2017;14:510\u201326. https:\/\/doi.org\/10.1038\/nrgastro.2017.79.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2102_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0040-1713440","volume":"37","author":"AK Goswami","year":"2020","unstructured":"Goswami AK, Khaja MS, Downing T, Kokabi N, Saad WE, Majdalany BS. Lymphatic anatomy and physiology. Semin Intervent Radiol. 2020;37:227\u201336. https:\/\/doi.org\/10.1055\/s-0040-1713440.","journal-title":"Semin Intervent Radiol"},{"key":"2102_CR35","unstructured":"Ilahi M, St Lucia K, Ilahi TB, Anatomy, Thorax TD. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 4]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513227\/. Accessed 4 Oct 2025."},{"key":"2102_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.suc.2010.04.017","volume":"90","author":"SRZ Abdel-Misih","year":"2010","unstructured":"Abdel-Misih SRZ, Bloomston M. Liver anatomy. Surg Clin North Am. 2010;90:643\u201353. https:\/\/doi.org\/10.1016\/j.suc.2010.04.017.","journal-title":"Surg Clin North Am"},{"key":"2102_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jgg.2022.03.012","volume":"49","author":"Y Yu","year":"2022","unstructured":"Yu Y, Liu B, Liu X, Zhang X, Zhang W, Tian H, et al. Mesenteric lymph system constitutes the second route in gut-liver axis and transports metabolism-modulating gut microbial metabolites. J Genet Genomics. 2022;49:612\u201323. https:\/\/doi.org\/10.1016\/j.jgg.2022.03.012.","journal-title":"J Genet Genomics"},{"key":"2102_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397\u2013411. https:\/\/doi.org\/10.1038\/s41575-018-0011-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2102_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13332","volume":"98","author":"K Chen","year":"2023","unstructured":"Chen K, Gu X, Yang S, Tao R, Fan M, Bao W, et al. Research progress on intestinal tissue-resident memory T cells in inflammatory bowel disease. Scand J Immunol. 2023;98:e13332. https:\/\/doi.org\/10.1111\/sji.13332.","journal-title":"Scand J Immunol"},{"key":"2102_CR40","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2147\/JIR.S353038","volume":"15","author":"Q Lu","year":"2022","unstructured":"Lu Q, Yang M-F, Liang Y-J, Xu J, Xu H-M, Nie Y-Q, et al. Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics. J Inflamm Res. 2022;15:1825\u201344. https:\/\/doi.org\/10.2147\/JIR.S353038.","journal-title":"J Inflamm Res"},{"key":"2102_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ecco-jcc\/jjw066","volume":"10","author":"A Carrasco","year":"2016","unstructured":"Carrasco A, Fern\u00e1ndez-Ba\u00f1ares F, Pedrosa E, Salas A, Loras C, Rosinach M, et al. Regional specialisation of T cell subsets and apoptosis in the human gut mucosa: differences between ileum and colon in healthy intestine and inflammatory bowel diseases. J Crohns Colitis. 2016;10:1042\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw066.","journal-title":"J Crohns Colitis"},{"key":"2102_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlife.2025.01.001","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yan H, Zheng Q, Sun X. The crucial function of gut microbiota on gut\u2013liver repair. hLife [Internet]. 2025. https:\/\/doi.org\/10.1016\/j.hlife.2025.01.001. [cited 2025 July 14].","journal-title":"hLife [Internet]"},{"key":"2102_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923599","author":"L Wang","year":"2022","unstructured":"Wang L, Cao Z-M, Zhang L-L, Li J, Lv W. The role of gut microbiota in some liver diseases: from an immunological perspective. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.923599.","journal-title":"Front Immunol"},{"key":"2102_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/cmi.2015.104","volume":"13","author":"C Ju","year":"2016","unstructured":"Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. 2016;13:316\u201327. https:\/\/doi.org\/10.1038\/cmi.2015.104.","journal-title":"Cell Mol Immunol"},{"key":"2102_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111140","volume":"399","author":"DZW Ng","year":"2024","unstructured":"Ng DZW, Low A, Tan AJH, Ong JH, Kwa WT, Lee JWJ, et al. Ex vivo metabolism kinetics of primary to secondary bile acids via a physiologically relevant human faecal microbiota model. Chem Biol Interact. 2024;399:111140. https:\/\/doi.org\/10.1016\/j.cbi.2024.111140.","journal-title":"Chem Biol Interact"},{"key":"2102_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","volume":"3","author":"P G\u00e9rard","year":"2013","unstructured":"G\u00e9rard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 2013;3:14\u201324. https:\/\/doi.org\/10.3390\/pathogens3010014.","journal-title":"Pathogens"},{"key":"2102_CR47","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/ijms22020784","volume":"22","author":"MI Sohail","year":"2021","unstructured":"Sohail MI, D\u00f6nmez-Cakil Y, Sz\u00f6ll\u0151si D, Stockner T, Chiba P. The bile salt export pump: molecular structure, study models and small-molecule drugs for the treatment of inherited BSEP deficiencies. Int J Mol Sci. 2021;22:784. https:\/\/doi.org\/10.3390\/ijms22020784.","journal-title":"Int J Mol Sci"},{"key":"2102_CR48","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","volume":"159","author":"AF Hofmann","year":"1999","unstructured":"Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159:2647\u201358. https:\/\/doi.org\/10.1001\/archinte.159.22.2647.","journal-title":"Arch Intern Med"},{"key":"2102_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","volume":"1","author":"JYL Chiang","year":"2017","unstructured":"Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017;1:3\u20139. https:\/\/doi.org\/10.1016\/j.livres.2017.05.001.","journal-title":"Liver Res"},{"key":"2102_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011356","volume":"19","author":"AD Mohammed","year":"2023","unstructured":"Mohammed AD, Ball RAW, Kubinak JL. The interplay between bile acids and mucosal adaptive immunity. PLoS Pathog. 2023;19:e1011356. https:\/\/doi.org\/10.1371\/journal.ppat.1011356.","journal-title":"PLoS Pathog"},{"key":"2102_CR51","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep4.1331","volume":"3","author":"N Ohtani","year":"2019","unstructured":"Ohtani N, Kawada N. Role of the gut\u2013liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship. Hepatol Commun. 2019;3:456\u201370. https:\/\/doi.org\/10.1002\/hep4.1331.","journal-title":"Hepatol Commun"},{"key":"2102_CR52","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s0168-8278(97)80338-8","volume":"27","author":"M Strazzabosco","year":"1997","unstructured":"Strazzabosco M. New insights into cholangiocyte physiology. J Hepatol. 1997;27:945\u201352. https:\/\/doi.org\/10.1016\/s0168-8278(97)80338-8.","journal-title":"J Hepatol"},{"key":"2102_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02155","volume":"11","author":"V Ronca","year":"2020","unstructured":"Ronca V, Wootton G, Milani C, Cain O. The immunological basis of liver allograft rejection. Front Immunol. 2020;11:2155. https:\/\/doi.org\/10.3389\/fimmu.2020.02155.","journal-title":"Front Immunol"},{"key":"2102_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1447878","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Wang L, Yi Q, Luo L, Xiong Y. Regulation of bile acids and their receptor FXR in metabolic diseases. Front Nutr. 2024;11:1447878. https:\/\/doi.org\/10.3389\/fnut.2024.1447878.","journal-title":"Front Nutr"},{"key":"2102_CR55","doi-asserted-by":"publisher","unstructured":"Tian Y, Gui W, Koo I, Smith PB, Allman EL, Nichols RG, et al. The microbiome modulating activity of bile acids. Gut Microbes. 2020;11:979\u201396. https:\/\/doi.org\/10.1080\/19490976.2020.1732268.","DOI":"10.1080\/19490976.2020.1732268"},{"key":"2102_CR56","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211018098","volume":"14","author":"R Sun","year":"2021","unstructured":"Sun R, Xu C, Feng B, Gao X, Liu Z. Critical roles of bile acids in regulating intestinal mucosal immune responses. Therap Adv Gastroenterol. 2021;14:17562848211018098. https:\/\/doi.org\/10.1177\/17562848211018098.","journal-title":"Therap Adv Gastroenterol"},{"key":"2102_CR57","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1073\/pnas.0509592103","volume":"103","author":"T Inagaki","year":"2006","unstructured":"Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103:3920\u20135. https:\/\/doi.org\/10.1073\/pnas.0509592103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2102_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcmgh.2024.02.015","volume":"18","author":"JM Ferrell","year":"2024","unstructured":"Ferrell JM, Dilts M, Pokhrel S, Stahl Z, Boehme S, Wang X, et al. Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease. Cell Mol Gastroenterol Hepatol. 2024;18:71\u201387. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.02.015.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2102_CR59","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1210\/er.2018-00134","volume":"39","author":"E Somm","year":"2018","unstructured":"Somm E, Jornayvaz FR. Fibroblast growth factor 15\/19: from basic functions to therapeutic perspectives. Endocr Rev. 2018;39:960\u201389. https:\/\/doi.org\/10.1210\/er.2018-00134.","journal-title":"Endocr Rev"},{"key":"2102_CR60","doi-asserted-by":"publisher","unstructured":"Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233\u20136. https:\/\/doi.org\/10.1126\/science.1121435.","DOI":"10.1126\/science.1121435"},{"key":"2102_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"K-H Song","year":"2009","unstructured":"Song K-H, Li T, Owsley E, Strom S, Chiang JYL. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009;49:297\u2013305. https:\/\/doi.org\/10.1002\/hep.22627.","journal-title":"Hepatology"},{"key":"2102_CR62","doi-asserted-by":"publisher","first-page":"s4","DOI":"10.5604\/01.3001.0010.5493","volume":"16","author":"A Di Ciaula","year":"2017","unstructured":"Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ-H, et al. Bile acid physiology. Ann Hepatol. 2017;16:s4\u201314. https:\/\/doi.org\/10.5604\/01.3001.0010.5493.","journal-title":"Ann Hepatol"},{"key":"2102_CR63","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/diabetes.52.5.1147","volume":"52","author":"FM Gribble","year":"2003","unstructured":"Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147\u201354. https:\/\/doi.org\/10.2337\/diabetes.52.5.1147.","journal-title":"Diabetes"},{"key":"2102_CR64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, Vilsb\u00f8ll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14:390\u2013403. https:\/\/doi.org\/10.1038\/s41574-018-0016-2.","journal-title":"Nat Rev Endocrinol"},{"key":"2102_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1152\/physiol.00048.2018","volume":"34","author":"SM Najjar","year":"2019","unstructured":"Najjar SM, Perdomo G, American Physiological Society. Hepatic insulin clearance: mechanism and physiology. Physiology. 2019;34:198\u2013215. https:\/\/doi.org\/10.1152\/physiol.00048.2018.","journal-title":"Physiology"},{"key":"2102_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00576","author":"C Xie","year":"2018","unstructured":"Xie C, Wang X, Young RL, Horowitz M, Rayner CK, Wu T. Role of intestinal bitter sensing in enteroendocrine hormone secretion and metabolic control. Front Endocrinol. 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00576.","journal-title":"Front Endocrinol"},{"key":"2102_CR67","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1172\/JCI16801","volume":"114","author":"DQ-H Wang","year":"2004","unstructured":"Wang DQ-H, Schmitz F, Kopin AS, Carey MC. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J Clin Invest. 2004;114:521\u20138. https:\/\/doi.org\/10.1172\/JCI16801.","journal-title":"J Clin Invest"},{"key":"2102_CR68","unstructured":"Okonkwo O, Zezoff D, Adeyinka A, Biochemistry. Cholecystokinin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 4]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534204\/. Accessed 4 Oct 2025."},{"key":"2102_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419892985","volume":"13","author":"C Guida","year":"2020","unstructured":"Guida C, Ramracheya R. PYY, a therapeutic option for type 2 diabetes? Clin Med Insights Endocrinol Diabetes. 2020;13:1179551419892985. https:\/\/doi.org\/10.1177\/1179551419892985.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2102_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4329\/wjr.v15.i1.1","volume":"15","author":"A Firat","year":"2023","unstructured":"Firat A, Abbasoglu TT, Karcaaltincaba M, Balaban YH. Clinical anatomy of hepatic vessels by computed tomography angiography: a minireview. World J Radiol. 2023;15:1\u20139. https:\/\/doi.org\/10.4329\/wjr.v15.i1.1.","journal-title":"World J Radiol"},{"key":"2102_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0716-8","volume":"10","author":"C Carneiro","year":"2019","unstructured":"Carneiro C, Brito J, Bilreiro C, Barros M, Bahia C, Santiago I, et al. All about portal vein: a pictorial display to anatomy, variants and physiopathology. Insights Imaging. 2019;10:38. https:\/\/doi.org\/10.1186\/s13244-019-0716-8.","journal-title":"Insights Imaging"},{"key":"2102_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/628157","volume":"2015","author":"A Michielan","year":"2015","unstructured":"Michielan A, D\u2019Inc\u00e0 R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157. https:\/\/doi.org\/10.1155\/2015\/628157.","journal-title":"Mediators Inflamm"},{"key":"2102_CR73","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/microorganisms13061188","volume":"13","author":"P Saha","year":"2025","unstructured":"Saha P, Hartmann P. Impact of gut microbiome on gut permeability in liver and gut diseases. Microorganisms Multidisciplinary Digit Publishing Inst. 2025;13:1188. https:\/\/doi.org\/10.3390\/microorganisms13061188.","journal-title":"Microorganisms Multidisciplinary Digit Publishing Inst"},{"key":"2102_CR74","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz039","volume":"4","author":"SS Ghosh","year":"2020","unstructured":"Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4:bvz039. https:\/\/doi.org\/10.1210\/jendso\/bvz039.","journal-title":"J Endocr Soc"},{"key":"2102_CR75","unstructured":"Basit H, Tan ML, Webster DR, Histology. Kupffer Cell. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 4]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493226\/. Accessed 4 Oct 2025."},{"key":"2102_CR76","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hep.1840160320","volume":"16","author":"PW Kowalski-Saunders","year":"1992","unstructured":"Kowalski-Saunders PW, Winwood PJ, Arthur MJ, Wright R. Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines. Hepatology. 1992;16:733\u201341. https:\/\/doi.org\/10.1002\/hep.1840160320.","journal-title":"Hepatology"},{"key":"2102_CR77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0014-2999(98)00988-1","volume":"368","author":"N Milosevic","year":"1999","unstructured":"Milosevic N, Schawalder H, Maier P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur J Pharmacol. 1999;368:75\u201387. https:\/\/doi.org\/10.1016\/S0014-2999(98)00988-1.","journal-title":"Eur J Pharmacol"},{"key":"2102_CR78","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1126\/science.1193478","volume":"330","author":"J Rittle","year":"2010","unstructured":"Rittle J, Green T. Cytochrome P450, compound I: capture, characterization, and C-H bond activation kinetics. Sci (New York NY). 2010;330:933\u20137. https:\/\/doi.org\/10.1126\/science.1193478.","journal-title":"Sci (New York NY)"},{"key":"2102_CR79","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.ajpath.2016.06.003","volume":"186","author":"K Sato","year":"2016","unstructured":"Sato K, Hall C, Glaser S, Francis H, Meng F, Alpini G. Pathogenesis of Kupffer cells in cholestatic liver injury. Am J Pathol. 2016;186:2238\u201347. https:\/\/doi.org\/10.1016\/j.ajpath.2016.06.003.","journal-title":"Am J Pathol"},{"key":"2102_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107598","volume":"101","author":"S Singh","year":"2021","unstructured":"Singh S, Anshita D, Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101:107598. https:\/\/doi.org\/10.1016\/j.intimp.2021.107598.","journal-title":"Int Immunopharmacol"},{"key":"2102_CR81","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3748\/wjg.v25.i5.521","volume":"25","author":"KJ Mehta","year":"2019","unstructured":"Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol. 2019;25:521\u201338. https:\/\/doi.org\/10.3748\/wjg.v25.i5.521.","journal-title":"World J Gastroenterol"},{"key":"2102_CR82","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","volume":"12","author":"G Kolios","year":"2006","unstructured":"Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12:7413\u201320. https:\/\/doi.org\/10.3748\/wjg.v12.i46.7413.","journal-title":"World J Gastroenterol"},{"key":"2102_CR83","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nri1784","volume":"6","author":"DH Adams","year":"2006","unstructured":"Adams DH, Eksteen B, Nature Publishing Group. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6:244\u201351. https:\/\/doi.org\/10.1038\/nri1784.","journal-title":"Nat Rev Immunol"},{"key":"2102_CR84","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18:45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8.","journal-title":"Cell Mol Immunol"},{"key":"2102_CR85","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep4.1356","volume":"3","author":"A Guillot","year":"2019","unstructured":"Guillot A, Tacke F. Liver macrophages: old dogmas and new insights. Hepatol Commun. 2019;3:730. https:\/\/doi.org\/10.1002\/hep4.1356.","journal-title":"Hepatol Commun"},{"key":"2102_CR86","doi-asserted-by":"publisher","unstructured":"Ouyang R, Li X, Hao J, Lin J, Lan H, Peng J, et al. Decoding the heterogeneity of liver-resident macrophages in chronic liver diseases: therapeutic responses to immunomodulatory strategies. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1708240.","DOI":"10.3389\/fphar.2025.1708240"},{"key":"2102_CR87","doi-asserted-by":"publisher","unstructured":"Huang H-Y, Chen Y-Z, Zhao C, Zheng X-N, Yu K, Yue J-X, et al. Alternations in inflammatory macrophage niche drive phenotypic and functional plasticity of Kupffer cells. Nat Commun. 2024;15:9337. https:\/\/doi.org\/10.1038\/s41467-024-53659-7.","DOI":"10.1038\/s41467-024-53659-7"},{"key":"2102_CR88","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41423-025-01343-1","volume":"22","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guan Y, Feng D, Maccioni L, Parra MA, Peiffer B, et al. Infiltrating macrophages replace Kupffer cells and play diverse roles in severe alcohol-associated hepatitis. Cell Mol Immunol Nat Publishing Group. 2025;22:1262\u201375. https:\/\/doi.org\/10.1038\/s41423-025-01343-1.","journal-title":"Cell Mol Immunol Nat Publishing Group"},{"key":"2102_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2025-100189","author":"D Feng","year":"2025","unstructured":"Feng D, Guan Y, Wang Y, Maccioni L, Mackowiak B, Gao B. Characterisation of macrophages in healthy and diseased livers in mice: identification of necrotic lesion-associated macrophages. eGastroenterology. 2025. https:\/\/doi.org\/10.1136\/egastro-2025-100189.","journal-title":"eGastroenterology"},{"key":"2102_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100960","author":"H Shi","year":"2024","unstructured":"Shi H, Moore MP, Wang X, Tabas I. Efferocytosis in liver disease. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100960.","journal-title":"JHEP Rep"},{"key":"2102_CR91","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/excr.1996.0123","volume":"224","author":"L Falasca","year":"1996","unstructured":"Falasca L, Bergamini A, Serafino A, Balabaud C, Dini L. Human Kupffer cell recognition and phagocytosis of apoptotic peripheral blood lymphocytes. Exp Cell Res. 1996;224:152\u201362. https:\/\/doi.org\/10.1006\/excr.1996.0123.","journal-title":"Exp Cell Res"},{"key":"2102_CR92","doi-asserted-by":"publisher","first-page":"e000003","DOI":"10.1136\/egastro-2023-000003","volume":"1","author":"A Guillot","year":"2023","unstructured":"Guillot A, Tacke F. Spatial dimension of macrophage heterogeneity in liver diseases. eGastroenterology. 2023;1:e000003. https:\/\/doi.org\/10.1136\/egastro-2023-000003.","journal-title":"eGastroenterology"},{"key":"2102_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82:134\u201353. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.032.","journal-title":"J Hepatol"},{"key":"2102_CR94","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877\u201387. https:\/\/doi.org\/10.1002\/hep.22848.","journal-title":"Hepatology"},{"key":"2102_CR95","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1530-0277.2007.00584.x","volume":"32","author":"Y Tang","year":"2008","unstructured":"Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:355\u201364. https:\/\/doi.org\/10.1111\/j.1530-0277.2007.00584.x.","journal-title":"Alcohol Clin Exp Res"},{"key":"2102_CR96","doi-asserted-by":"publisher","first-page":"e1004559","DOI":"10.1371\/journal.ppat.1004559","volume":"11","author":"J Boursier","year":"2015","unstructured":"Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLOS Pathogens Public Libr Sci. 2015;11:e1004559. https:\/\/doi.org\/10.1371\/journal.ppat.1004559.","journal-title":"PLOS Pathogens Public Libr Sci"},{"key":"2102_CR97","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32:197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"key":"2102_CR98","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/apt.16879","volume":"55","author":"M Zamani","year":"2022","unstructured":"Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:894\u2013907. https:\/\/doi.org\/10.1111\/apt.16879.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186418","author":"SL Friedman","year":"2025","unstructured":"Friedman SL, American Society for Clinical Investigation. Fat, fibrosis, and the future: navigating the maze of MASLD\/MASH. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI186418.","journal-title":"J Clin Invest"},{"key":"2102_CR100","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jgh.15172","volume":"36","author":"S Yamamura","year":"2021","unstructured":"Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, et al. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of chronic liver disease Questionnaire-non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021;36:629\u201336. https:\/\/doi.org\/10.1111\/jgh.15172.","journal-title":"J Gastroenterol Hepatol"},{"key":"2102_CR101","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/17474124.2025.2464037","volume":"19","author":"GGM Scarlata","year":"2025","unstructured":"Scarlata GGM, Abenavoli L. Gut microbiota: the pathogenetic bridge between inflammatory bowel disease and metabolic-associated steatotic liver disease. Expert Rev Gastroenterol Hepatol. 2025;19:85\u20138. https:\/\/doi.org\/10.1080\/17474124.2025.2464037.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2102_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911689","volume":"23","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Iwaki M, Nakajima A, Nogami A, Yoneda M. Current research on the pathogenesis of NAFLD\/NASH and the gut\u2013liver axis: gut microbiota, dysbiosis, and leaky-gut syndrome. Int J Mol Sci. 2022;23:11689. https:\/\/doi.org\/10.3390\/ijms231911689.","journal-title":"Int J Mol Sci"},{"key":"2102_CR103","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/nu15214507","volume":"15","author":"P Navarro","year":"2023","unstructured":"Navarro P, Guti\u00e9rrez-Ram\u00edrez L, Tejera-Mu\u00f1oz A, Arias \u00c1, Lucendo AJ. Systematic review and meta-analysis: prevalence of non-alcoholic fatty liver disease and liver fibrosis in patients with inflammatory bowel disease. Nutrients. 2023;15:4507. https:\/\/doi.org\/10.3390\/nu15214507.","journal-title":"Nutrients"},{"key":"2102_CR104","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/ibd\/izad175","volume":"30","author":"SJ Mart\u00ednez-Dom\u00ednguez","year":"2024","unstructured":"Mart\u00ednez-Dom\u00ednguez SJ, Garc\u00eda-Mateo S, Gargallo-Puyuelo CJ, Gallego-Llera B, Callau P, Mendi C, et al. Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals. Inflamm Bowel Dis. 2024;30:1274\u201383. https:\/\/doi.org\/10.1093\/ibd\/izad175.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/life14101226","volume":"14","author":"L Abenavoli","year":"2024","unstructured":"Abenavoli L, Spagnuolo R, Scarlata GGM, Gambardella ML, Boccuto L, M\u00e9ndez-S\u00e1nchez N, et al. Metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel diseases: a pilot study. Life. 2024;14:1226. https:\/\/doi.org\/10.3390\/life14101226.","journal-title":"Life"},{"key":"2102_CR106","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.cgh.2019.02.045","volume":"17","author":"S McHenry","year":"2019","unstructured":"McHenry S, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, et al. Crohn\u2019s disease is associated with an increased prevalence of non-alcoholic fatty liver disease: a cross-sectional study using Magnetic Resonance Proton Density Fat Fraction Mapping. Clin Gastroenterol Hepatol. 2019;17:2816\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2019.02.045.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2102_CR107","doi-asserted-by":"publisher","first-page":"i871","DOI":"10.1093\/ecco-jcc\/jjae190.0557","volume":"19","author":"ECSD Oliveira","year":"2025","unstructured":"Oliveira ECSD, Lopes MA, Beraldo RF, Castelhano NS, Baima JP, Herrerias GSP, et al. P0383 factors associated with steatotic liver disease associated with metabolic dysfunction (MASLD) in patients with inflammatory bowel disease (IBD). J Crohns Colitis. 2025;19:i871. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0557.","journal-title":"J Crohns Colitis"},{"key":"2102_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/life15020288","volume":"15","author":"A Rotaru","year":"2025","unstructured":"Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, Minea H, et al. Lean MASLD and IBD: exploring the intersection of metabolic dysfunction and the gut\u2013liver axis. Life Multidisciplinary Digital Publishing Institute. 2025;15:288. https:\/\/doi.org\/10.3390\/life15020288.","journal-title":"Life. Multidisciplinary Digital Publishing Institute"},{"key":"2102_CR109","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10620-017-4495-0","volume":"62","author":"RM Carr","year":"2017","unstructured":"Carr RM, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A, et al. Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci. 2017;62:1354\u201361. https:\/\/doi.org\/10.1007\/s10620-017-4495-0.","journal-title":"Dig Dis Sci"},{"key":"2102_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0124-2","volume":"9","author":"A Sartini","year":"2018","unstructured":"Sartini A, Gitto S, Bianchini M, Verga MC, Di Girolamo M, Bertani A, et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018;9:87. https:\/\/doi.org\/10.1038\/s41419-017-0124-2.","journal-title":"Cell Death Dis"},{"key":"2102_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206450","volume":"13","author":"LC Adams","year":"2018","unstructured":"Adams LC, L\u00fcbbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study. PLoS One. 2018;13:e0206450. https:\/\/doi.org\/10.1371\/journal.pone.0206450.","journal-title":"PLoS One"},{"key":"2102_CR112","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s10620-015-3629-5","volume":"60","author":"A Flores","year":"2015","unstructured":"Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci. 2015;60:2436\u201345. https:\/\/doi.org\/10.1007\/s10620-015-3629-5.","journal-title":"Dig Dis Sci"},{"key":"2102_CR113","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.3748\/wjg.v26.i47.7528","volume":"26","author":"G Losurdo","year":"2020","unstructured":"Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, et al. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. World J Gastroenterol. 2020;26:7528\u201337. https:\/\/doi.org\/10.3748\/wjg.v26.i47.7528.","journal-title":"World J Gastroenterol"},{"key":"2102_CR114","doi-asserted-by":"publisher","first-page":"i810","DOI":"10.1093\/ecco-jcc\/jjac190.0809","volume":"17","author":"S Madigan","year":"2023","unstructured":"Madigan S, Mountifield R, Barnes A. P679 is the burden of obesity in IBD bigger than just weight? J Crohns Colitis. 2023;17:i810. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0809.","journal-title":"J Crohns Colitis"},{"key":"2102_CR115","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s10620-024-08504-8","volume":"69","author":"M Mahmoud","year":"2024","unstructured":"Mahmoud M, Syn W-K. Impact of Obesity and Metabolic Syndrome on IBD Outcomes. Dig Dis Sci. 2024;69:2741\u201353. https:\/\/doi.org\/10.1007\/s10620-024-08504-8.","journal-title":"Dig Dis Sci"},{"key":"2102_CR116","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1097\/MIB.0000000000000560","volume":"21","author":"JL Seminerio","year":"2015","unstructured":"Seminerio JL, Koutroubakis IE, Ramos-Rivers C, Hashash JG, Dudekula A, Regueiro M, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease: Inflamm Bowel Dis. 2015;21:2857\u201363. https:\/\/doi.org\/10.1097\/MIB.0000000000000560.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR117","doi-asserted-by":"publisher","first-page":"i1991","DOI":"10.1093\/ecco-jcc\/jjad212.1247","volume":"18","author":"C Rivas","year":"2024","unstructured":"Rivas C, Garc\u00eda-Nieto E, Rodr\u00edguez-Duque JC, Garc\u00eda-Mateo S, Alonso Fern\u00e1ndez S, Echavarria Rodriguez V, et al. P1117 molecular and clinical characterization of metabolic associated steatotic liver disease in the setting of immune-mediated inflammatory diseases: a link with cancer risk in IBD? J Crohns Colitis. 2024;18:i1991\u20132. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.1247.","journal-title":"J Crohns Colitis"},{"key":"2102_CR118","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jcag\/gwad061.259","volume":"7","author":"D Kablawi","year":"2024","unstructured":"Kablawi D, Sasson S, Aljohani F, Palumbo CS, Bitton A, Afif W, et al. A259 metabolic dysfunction-associated steatotic liver disease is associated with multi-organ comorbidities and fibrosis progression in patients with inflammatory bowel disease (IBD). J Can Assoc Gastroenterol. 2024;7:208\u20139. https:\/\/doi.org\/10.1093\/jcag\/gwad061.259.","journal-title":"J Can Assoc Gastroenterol"},{"key":"2102_CR119","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5217\/ir.2023.00078","volume":"23","author":"Y-H Wang","year":"2025","unstructured":"Wang Y-H, Chung C-H, Huang T-Y, Chang C-F, Yang C-W, Chien W-C, et al. Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population\u2011based cohort study. Intest Res. 2025;23:76\u201384. https:\/\/doi.org\/10.5217\/ir.2023.00078.","journal-title":"Intest Res"},{"key":"2102_CR120","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","volume":"25","author":"S Magr\u00ec","year":"2019","unstructured":"Magr\u00ec S, Paduano D, Chicco F, Cingolani A, Farris C, Delogu G, et al. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history. World J Gastroenterol. 2019;25:5676\u201386. https:\/\/doi.org\/10.3748\/wjg.v25.i37.5676.","journal-title":"World J Gastroenterol"},{"key":"2102_CR121","doi-asserted-by":"publisher","first-page":"109035","DOI":"10.4254\/wjh.v17.i9.109035","volume":"17","author":"MA Lopes","year":"2025","unstructured":"Lopes MA, Oliveira ECS, Quaglio AEV, Santos A, Imbrizi M, Mendes LER, et al. From gut to liver: exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2025;17:109035. https:\/\/doi.org\/10.4254\/wjh.v17.i9.109035.","journal-title":"World J Hepatol"},{"key":"2102_CR122","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.07.020","volume":"154","author":"CP Woods","year":"2015","unstructured":"Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94\u2013103. https:\/\/doi.org\/10.1016\/j.jsbmb.2015.07.020.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2102_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2025-100196","author":"P Horn","year":"2025","unstructured":"Horn P, Tacke F, BMJ Publishing Group Ltd. Key takeaways from the updated multidisciplinary European MASLD guidelines. egastro. 2025. https:\/\/doi.org\/10.1136\/egastro-2025-100196.","journal-title":"egastro"},{"key":"2102_CR124","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms26136518","volume":"26","author":"K Drygalski","year":"2025","unstructured":"Drygalski K. Pharmacological treatment of MASLD: contemporary treatment and future perspectives. Int J Mol Sci. 2025;26:6518. https:\/\/doi.org\/10.3390\/ijms26136518.","journal-title":"Int J Mol Sci"},{"key":"2102_CR125","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","volume":"77","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC-H, Yu J. Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: current and emerging therapeutic options. Pharmacol Rev. 2025;77:100018. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018.","journal-title":"Pharmacol Rev"},{"key":"2102_CR126","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Resmetirom. First Approval Drugs. 2024;84:729\u201335. https:\/\/doi.org\/10.1007\/s40265-024-02045-0.","journal-title":"First Approval Drugs"},{"key":"2102_CR127","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/clinem\/dgaf336","volume":"110","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhou Y, Wang Z, Ni Y, Prud\u2019homme GJ, Wang Q. Efficacy of GLP-1-based therapies on metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2025;110:2964\u201379. https:\/\/doi.org\/10.1210\/clinem\/dgaf336.","journal-title":"J Clin Endocrinol Metab"},{"key":"2102_CR128","doi-asserted-by":"publisher","first-page":"r1788","DOI":"10.1136\/bmj.r1788","volume":"390","author":"K Bowie","year":"2025","unstructured":"Bowie K, Semaglutide. FDA approves weight loss Jab to treat severe liver disease. BMJ Br Med J Publishing Group. 2025;390:r1788. https:\/\/doi.org\/10.1136\/bmj.r1788.","journal-title":"BMJ Br Med J Publishing Group"},{"key":"2102_CR129","doi-asserted-by":"publisher","unstructured":"Birda CL, Ibrahim F, Chatterjee A, Jena A, Sharma V, Sebastian S. Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review. Autoimmun Rev. 2025;103936. https:\/\/doi.org\/10.1016\/j.autrev.2025.103936.","DOI":"10.1016\/j.autrev.2025.103936"},{"key":"2102_CR130","doi-asserted-by":"publisher","first-page":"1610368","DOI":"10.3389\/fimmu.2025.1610368","volume":"16","author":"G Migliorisi","year":"2025","unstructured":"Migliorisi G, Gabbiadini R, Dal Buono A, Ferraris M, Privitera G, Petronio L, et al. GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation. Front Immunol. 2025;16:1610368. https:\/\/doi.org\/10.3389\/fimmu.2025.1610368.","journal-title":"Front Immunol"},{"key":"2102_CR131","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2102_CR132","doi-asserted-by":"publisher","first-page":"eadh1641","DOI":"10.1126\/scisignal.adh1641","volume":"17","author":"T Mukherjee","year":"2024","unstructured":"Mukherjee T, Kumar N, Chawla M, Philpott DJ, Basak S. The NF-\u03baB signaling system in the Immunopathogenesis of inflammatory bowel disease. Sci Signal. 2024;17:eadh1641. https:\/\/doi.org\/10.1126\/scisignal.adh1641.","journal-title":"Sci Signal"},{"key":"2102_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47050383","volume":"47","author":"AG Gravina","year":"2025","unstructured":"Gravina AG, Pellegrino R, Izzo M, De Costanzo I, Imperio G, Landa F, et al. Relevance of glucagon-like peptide 1 (GLP-1) in inflammatory bowel diseases: a narrative review. Curr Issues Mol Biol. 2025;47:383. https:\/\/doi.org\/10.3390\/cimb47050383.","journal-title":"Curr Issues Mol Biol"},{"key":"2102_CR134","unstructured":"Damas OM. A Randomized Clinical Trial to Determine the Effect of Dual Glucose-dependent Insulinotropic Polypeptide (GIP)\/GLP-1 Receptor Agonist-mediated Weight Loss and Diet on Crohn\u2019s Disease Clinical Response: a Pilot Study [Internet]. clinicaltrials.gov;2025 Apr. Report No.: NCT06774079. https:\/\/clinicaltrials.gov\/study\/NCT06774079. Accessed 27 Oct 2025."},{"key":"2102_CR135","unstructured":"Fondation H\u00f4pital Saint-Joseph. Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD) [Internet]. clinicaltrials.gov; 2023 Mar. Report No.: NCT05196958. https:\/\/clinicaltrials.gov\/study\/NCT05196958. Accessed 27 Oct 2025."},{"key":"2102_CR136","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231207348","volume":"14","author":"S Rella","year":"2023","unstructured":"Rella S, Onyiah J, Baker C, Singh V, Her A, Rasouli N. Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2023;14:20420188231207348. https:\/\/doi.org\/10.1177\/20420188231207348.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2102_CR137","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/ibd\/izae147","volume":"31","author":"JC Petrov","year":"2025","unstructured":"Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, et al. Metformin is associated with improved inflammatory bowel disease outcomes in patients with type 2 diabetes mellitus: A Propensity-Matched cohort study. Inflamm Bowel Dis. 2025;31:1237\u201347. https:\/\/doi.org\/10.1093\/ibd\/izae147.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR138","first-page":"S1","volume":"10","author":"N Amiri Dash Atan","year":"2017","unstructured":"Amiri Dash Atan N, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10:S1\u20137.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2102_CR139","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"key":"2102_CR140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135858","volume":"10","author":"S-Y Lee","year":"2015","unstructured":"Lee S-Y, Lee SH, Yang E-J, Kim E-K, Kim J-K, Shin D-Y, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance. PLoS One. 2015;10:e0135858. https:\/\/doi.org\/10.1371\/journal.pone.0135858.","journal-title":"PLoS One"},{"key":"2102_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-025-04821-0","volume":"40","author":"L Chen","year":"2025","unstructured":"Chen L, Xu Y, Ai F, Shen S, Luo Y, Li X. Dissecting the rising tide of inflammatory bowel disease among youth in a changing world: insights from GBD 2021. Int J Colorectal Dis. 2025;40:44. https:\/\/doi.org\/10.1007\/s00384-025-04821-0.","journal-title":"Int J Colorectal Dis"},{"key":"2102_CR142","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/ibd\/izab199","volume":"28","author":"S Noorian","year":"2022","unstructured":"Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases: nationwide analysis. Inflamm Bowel Dis. 2022;28:878\u201387. https:\/\/doi.org\/10.1093\/ibd\/izab199.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR143","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"M Thursz","year":"2018","unstructured":"Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, et al. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.018.","journal-title":"J Hepatol"},{"key":"2102_CR144","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000133","volume":"7","author":"S Amonker","year":"2023","unstructured":"Amonker S, Houshmand A, Hinkson A, Rowe I, Parker R. Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis. Hepatol Commun. 2023;7:e0133. https:\/\/doi.org\/10.1097\/HC9.0000000000000133.","journal-title":"Hepatol Commun"},{"key":"2102_CR145","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MEG.0000000000002453","volume":"35","author":"M Martinho-Grueber","year":"2023","unstructured":"Martinho-Grueber M, Kapoglou I, Bravo F, Sarraj R, Benz E, Restellini S, et al. Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease. Eur J Gastroenterol Hepatol. 2023;35:21\u201330. https:\/\/doi.org\/10.1097\/MEG.0000000000002453.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2102_CR146","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.3748\/wjg.v20.i33.11684","volume":"20","author":"C Torruellas","year":"2014","unstructured":"Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol. 2014;20:11684\u201399. https:\/\/doi.org\/10.3748\/wjg.v20.i33.11684.","journal-title":"World J Gastroenterol"},{"key":"2102_CR147","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00109-022-02254-8","volume":"100","author":"K Ferrao","year":"2022","unstructured":"Ferrao K, Ali N, Mehta KJ. Iron and iron-related proteins in alcohol consumers: cellular and clinical aspects. J Mol Med (Berl). 2022;100:1673\u201389. https:\/\/doi.org\/10.1007\/s00109-022-02254-8.","journal-title":"J Mol Med (Berl)"},{"key":"2102_CR148","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ajpath.2022.08.010","volume":"193","author":"N Ali","year":"2023","unstructured":"Ali N, Ferrao K, Mehta KJ. Liver iron loading in alcohol-associated liver disease. Am J Pathol. 2023;193:1427\u201339. https:\/\/doi.org\/10.1016\/j.ajpath.2022.08.010.","journal-title":"Am J Pathol"},{"key":"2102_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.918754","author":"B-X Liu","year":"2022","unstructured":"Liu B-X, Yang J, Zeng C, Dai X-J, Chen Y. Risk of inflammatory bowel disease appears to vary across different frequency, amount, and subtype of alcoholic beverages. Front Nutr. 2022. https:\/\/doi.org\/10.3389\/fnut.2022.918754.","journal-title":"Front Nutr"},{"key":"2102_CR150","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.alcohol.2009.10.019","volume":"44","author":"GR Swanson","year":"2010","unstructured":"Swanson GR, Sedghi S, Farhadi A, Keshavarzian A. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol. 2010;44:223\u20138. https:\/\/doi.org\/10.1016\/j.alcohol.2009.10.019.","journal-title":"Alcohol"},{"key":"2102_CR151","first-page":"211","volume":"17","author":"G Piovezani Ramos","year":"2021","unstructured":"Piovezani Ramos G, Kane S. Alcohol use in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2021;17:211\u201325.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2102_CR152","first-page":"425","volume":"13","author":"TR Morgan","year":"2017","unstructured":"Morgan TR. Treatment of alcoholic liver disease. Gastroenterol Hepatol (N Y). 2017;13:425\u20137.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2102_CR153","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100013","volume":"1","author":"L Maccioni","year":"2023","unstructured":"Maccioni L, Fu Y, Horsmans Y, Leclercq I, St\u00e4rkel P, Kunos G, et al. Alcohol-associated bowel disease: new insights into pathogenesis. eGastroenterology. 2023;1:e100013. https:\/\/doi.org\/10.1136\/egastro-2023-100013.","journal-title":"eGastroenterology"},{"key":"2102_CR154","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/apt.17177","volume":"56","author":"L Maccioni","year":"2022","unstructured":"Maccioni L, Loriot A, Dewulf J, Bommer G, Horsmans Y, Lanthier N, et al. Duodenal CD8\u2009+\u2009T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans. Aliment Pharmacol Ther. 2022;56:1055\u201370. https:\/\/doi.org\/10.1111\/apt.17177.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR155","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41586-025-09395-z","volume":"646","author":"C Llorente","year":"2025","unstructured":"Llorente C, Raya Tonetti F, Bruellman R, Brea R, Pell N, Hartmann P, et al. mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity. Nature. 2025;646:180\u20139. https:\/\/doi.org\/10.1038\/s41586-025-09395-z.","journal-title":"Nature"},{"key":"2102_CR156","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ajpath.2015.12.016","volume":"186","author":"R Al-Sadi","year":"2016","unstructured":"Al-Sadi R, Guo S, Ye D, Rawat M, Ma TY. TNF-\u03b1 modulation of intestinal tight junction permeability is mediated by NIK\/IKK-\u03b1 axis activation of the canonical NF-\u03baB pathway. Am J Pathol. 2016;186:1151\u201365. https:\/\/doi.org\/10.1016\/j.ajpath.2015.12.016.","journal-title":"Am J Pathol"},{"key":"2102_CR157","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100013","volume":"1","author":"L Maccioni","year":"2023","unstructured":"Maccioni L, Fu Y, Horsmans Y, Leclercq I, St\u00e4rkel P, Kunos G, et al. Alcohol-associated bowel disease: new insights into pathogenesis. eGastroenterology. 2023;1:e100013. https:\/\/doi.org\/10.1136\/egastro-2023-100013.","journal-title":"eGastroenterology"},{"key":"2102_CR158","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2024-100173","volume":"3","author":"L Maccioni","year":"2025","unstructured":"Maccioni L, Dvor\u00e1csk\u00f3 S, Godlewski G, Cinar R, Iyer MR, Gao B, et al. Gut cannabinoid receptor 1 regulates alcohol binge-induced intestinal permeability. eGastroenterology. 2025;3:e100173. https:\/\/doi.org\/10.1136\/egastro-2024-100173.","journal-title":"eGastroenterology"},{"key":"2102_CR159","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1136\/gutjnl-2024-334412","volume":"74","author":"L Maccioni","year":"2025","unstructured":"Maccioni L, Guan Y, Kim M, Parra MA, Peiffer B, Fu Y, et al. Opposite regulation of intestinal and intrahepatic CD8\u2009+\u2009T cells controls alcohol-associated liver disease progression. Gut. 2025;74:1308\u201320. https:\/\/doi.org\/10.1136\/gutjnl-2024-334412.","journal-title":"Gut"},{"key":"2102_CR160","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-immunol-020711-075001","volume":"30","author":"JM Brenchley","year":"2012","unstructured":"Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol. 2012;30:149\u201373. https:\/\/doi.org\/10.1146\/annurev-immunol-020711-075001.","journal-title":"Annu Rev Immunol"},{"key":"2102_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.703310","volume":"9","author":"R Linares","year":"2021","unstructured":"Linares R, Franc\u00e9s R, Guti\u00e9rrez A, Juanola O. Bacterial translocation as inflammatory driver in Crohn\u2019s disease. Front Cell Dev Biol. 2021;9:703310. https:\/\/doi.org\/10.3389\/fcell.2021.703310.","journal-title":"Front Cell Dev Biol"},{"key":"2102_CR162","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1782157","volume":"12","author":"L Maccioni","year":"2020","unstructured":"Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, et al. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes. 2020;12:1782157. https:\/\/doi.org\/10.1080\/19490976.2020.1782157.","journal-title":"Gut Microbes"},{"key":"2102_CR163","doi-asserted-by":"publisher","first-page":"88519","DOI":"10.5662\/wjm.v14.i1.88519","volume":"14","author":"I Koutromanos","year":"2024","unstructured":"Koutromanos I, Legaki E, Gazouli M, Vasilopoulos E, Kouzoupis A, Tzavellas E. Gut microbiome in alcohol use disorder: implications for health outcomes and therapeutic strategies-a literature review. World J Methodol. 2024;14:88519. https:\/\/doi.org\/10.5662\/wjm.v14.i1.88519.","journal-title":"World J Methodol"},{"key":"2102_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03621-z","volume":"7","author":"J Batah","year":"2017","unstructured":"Batah J, Kobeissy H, Bui Pham PT, Den\u00e8ve-Larrazet C, Kuehne S, Collignon A, et al. Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. Sci Rep. 2017;7:3256. https:\/\/doi.org\/10.1038\/s41598-017-03621-z.","journal-title":"Sci Rep"},{"key":"2102_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.801892","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liu F, Xue J, Lee SA, Liu L, Riordan SM, et al. Bacterial species associated with human inflammatory bowel disease and their pathogenic mechanisms. Front Microbiol. 2022. https:\/\/doi.org\/10.3389\/fmicb.2022.801892.","journal-title":"Front Microbiol"},{"key":"2102_CR166","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ibd\/izab089","volume":"28","author":"BA White","year":"2022","unstructured":"White BA, Ramos GP, Kane S. The impact of alcohol in inflammatory bowel diseases. Inflamm Bowel Dis. 2022;28:466\u201373. https:\/\/doi.org\/10.1093\/ibd\/izab089.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR167","doi-asserted-by":"publisher","first-page":"872","DOI":"10.61336\/ejcm\/25-07-148","volume":"15","author":"SB Sutar","year":"2025","unstructured":"Sutar SB, Nageswar M, Majhi CK. Gut microbiota as a therapeutic target in alcoholic liver disease: a narrative review. Eur J Cardiovasc Med. 2025;15:872\u20136. https:\/\/doi.org\/10.61336\/ejcm\/25-07-148.","journal-title":"Eur J Cardiovasc Med"},{"key":"2102_CR168","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.alcohol.2008.03.131","volume":"42","author":"V Purohit","year":"2008","unstructured":"Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, et al. Alcohol, intestinal bacterial Growth, intestinal permeability to Endotoxin, and medical consequences. Alcohol. 2008;42:349\u201361. https:\/\/doi.org\/10.1016\/j.alcohol.2008.03.131.","journal-title":"Alcohol"},{"key":"2102_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1258062","author":"L Zhu","year":"2023","unstructured":"Zhu L, Wang Y, Pan CQ, Xing H, Frontiers. Gut microbiota in alcohol-related liver disease: pathophysiology and gut-brain cross talk. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1258062.","journal-title":"Front Pharmacol"},{"key":"2102_CR170","doi-asserted-by":"publisher","first-page":"147","DOI":"10.35946\/arcr.v38.2.01","volume":"38","author":"NA Osna","year":"2017","unstructured":"Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38:147\u201361.","journal-title":"Alcohol Res"},{"key":"2102_CR171","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14740\/gr990w","volume":"11","author":"FS Fousekis","year":"2018","unstructured":"Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary manifestations and complications in inflammatory bowel disease: a review. Gastroenterol Res. 2018;11:83\u201394. https:\/\/doi.org\/10.14740\/gr990w.","journal-title":"Gastroenterol Res"},{"key":"2102_CR172","first-page":"15","volume":"259","author":"JYJ Lee","year":"2015","unstructured":"Lee JYJ, Keane MG, Pereira S. Diagnosis and treatment of gallstone disease. Practitioner. 2015;259:15\u20139.","journal-title":"Practitioner"},{"key":"2102_CR173","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1586\/17474124.2016.1109445","volume":"10","author":"P Portincasa","year":"2016","unstructured":"Portincasa P, Di Ciaula A, de Bari O, Garruti G, Palmieri VO, Wang D-H. Management of gallstones and its related complications. Expert Rev Gastroenterol Hepatol. 2016;10:93\u2013112. https:\/\/doi.org\/10.1586\/17474124.2016.1109445.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2102_CR174","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0950-3528(92)90044-f","volume":"6","author":"AK Diehl","year":"1992","unstructured":"Diehl AK. Symptoms of gallstone disease. Baillieres Clin Gastroenterol. 1992;6:635\u201357. https:\/\/doi.org\/10.1016\/0950-3528(92)90044-f.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2102_CR175","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26121","author":"MMA Baig","year":"2022","unstructured":"Baig MMA, Irfan SA, Sumbal A, Sumbal R, Kumar S, Ahmad J, et al. Prevalence of gallstones in ulcerative colitis and crohn\u2019s disease: A systematic review and Meta-Analysis. Cureus [Internet] Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.26121. [cited 2025 Oct 26];14.","journal-title":"Cureus [Internet] Cureus"},{"key":"2102_CR176","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/ijerph15030513","volume":"15","author":"C-H Chen","year":"2018","unstructured":"Chen C-H, Lin C-L, Kao C-H. Association between inflammatory bowel disease and cholelithiasis: a nationwide population-based cohort study. Int J Environ Res Public Health. 2018;15:513. https:\/\/doi.org\/10.3390\/ijerph15030513.","journal-title":"Int J Environ Res Public Health"},{"issue":"Suppl 3","key":"2102_CR177","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/s1590-8658(03)00092-6","volume":"35","author":"Aa Masclee","year":"2003","unstructured":"Masclee Aa, Vu M. Gallbladder motility in inflammatory bowel diseases. Dig Liver Dis. 2003;35(Suppl 3):S35\u201338. https:\/\/doi.org\/10.1016\/s1590-8658(03)00092-6.","journal-title":"Dig Liver Dis"},{"key":"2102_CR178","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14309\/ajg.0000000000003111","volume":"120","author":"N Mi","year":"2025","unstructured":"Mi N, Yang M, Wei L, Nie P, Zhan S, Nguyen LH, et al. Gallstone disease is associated with an increased risk of inflammatory bowel disease: results from 3 prospective cohort studies. Am J Gastroenterol. 2025;120:204\u201312. https:\/\/doi.org\/10.14309\/ajg.0000000000003111.","journal-title":"Am J Gastroenterol"},{"key":"2102_CR179","doi-asserted-by":"publisher","first-page":"733","DOI":"10.4103\/0253-7613.89840","volume":"43","author":"V Moses","year":"2011","unstructured":"Moses V, Ramakrishna B, Thomas K. Azathioprine induced cholestatic hepatitis. Indian J Pharmacol. 2011;43:733\u20135. https:\/\/doi.org\/10.4103\/0253-7613.89840.","journal-title":"Indian J Pharmacol"},{"key":"2102_CR180","unstructured":"Jones MW, Weir CB, Marietta M. Gallstones (Cholelithiasis). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Sept 9]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459370\/. Accessed 9 Sept 2025."},{"key":"2102_CR181","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1007\/s10620-021-07273-y","volume":"67","author":"ELSA van Liere","year":"2022","unstructured":"van Liere ELSA, Bayoumy AB, Mulder CJJ, Warner B, Hayee B, Mateen BA, et al. Azathioprine with allopurinol is a promising First-Line therapy for inflammatory bowel diseases. Dig Dis Sci. 2022;67:4008\u201319. https:\/\/doi.org\/10.1007\/s10620-021-07273-y.","journal-title":"Dig Dis Sci"},{"key":"2102_CR182","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04726-4","volume":"39","author":"D Peng","year":"2024","unstructured":"Peng D, Yang S, Zhai H. The causal relationship between cholecystectomy and IBD\/IBS and the role of bile acids and gut microbiota: a two-sample Mendelian randomization study. Int J Colorectal Dis. 2024;39:149. https:\/\/doi.org\/10.1007\/s00384-024-04726-4.","journal-title":"Int J Colorectal Dis"},{"key":"2102_CR183","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2107387","volume":"14","author":"Y Liu","year":"2022","unstructured":"Liu Y, Xu J, Ren X, Zhang Y, Ke Z, Zhou J, et al. Cholecystectomy-induced secondary bile acids accumulation ameliorates colitis through inhibiting monocyte\/macrophage recruitment. Gut Microbes. 2022;14:2107387. https:\/\/doi.org\/10.1080\/19490976.2022.2107387.","journal-title":"Gut Microbes"},{"key":"2102_CR184","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ibd\/izaa076","volume":"27","author":"F Koutroumpakis","year":"2021","unstructured":"Koutroumpakis F, Lodhi M, Ahsan M, Ramos Rivers C, Schwartz M, Hashash JG, et al. The impact of cholecystectomy on Long-Term disease outcomes and quality of life in patients with crohn\u2019s disease. Inflamm Bowel Dis. 2021;27:336\u201343. https:\/\/doi.org\/10.1093\/ibd\/izaa076.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR185","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.chom.2020.01.021","volume":"27","author":"SR Sinha","year":"2020","unstructured":"Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe. 2020;27:659-670.e5. https:\/\/doi.org\/10.1016\/j.chom.2020.01.021.","journal-title":"Cell Host Microbe"},{"key":"2102_CR186","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-21-1","author":"L Kellermann","year":"2021","unstructured":"Kellermann L, Riis LB, AME Publishing Company. A close view on histopathological changes in inflammatory bowel disease, a narrative review. Dig Med Res. 2021. https:\/\/doi.org\/10.21037\/dmr-21-1.","journal-title":"Dig Med Res"},{"key":"2102_CR187","unstructured":"Hundt M, Basit H, John S, Physiology. Bile Secretion. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 4]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470209\/. Accessed 4 Oct 2025."},{"key":"2102_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00564","volume":"11","author":"LR Fitzpatrick","year":"2020","unstructured":"Fitzpatrick LR, Jenabzadeh P. IBD and bile acid absorption: focus on pre-clinical and clinical observations. Front Physiol. 2020;11:564. https:\/\/doi.org\/10.3389\/fphys.2020.00564.","journal-title":"Front Physiol"},{"key":"2102_CR189","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jgh3.12786","volume":"6","author":"A Hojo","year":"2022","unstructured":"Hojo A, Kobayashi T, Matsubayashi M, Morikubo H, Miyatani Y, Fukuda T, et al. Usefulness of colestimide for diarrhea in postoperative Crohn\u2019s disease. JGH Open. 2022;6:547\u201353. https:\/\/doi.org\/10.1002\/jgh3.12786.","journal-title":"JGH Open"},{"key":"2102_CR190","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjae175","volume":"2024","author":"TS Sidhu","year":"2024","unstructured":"Sidhu TS, Jhamb S, Ben David MM. A rare case of a cholecysto-duodenocolonic fistula secondary to cholelithiasis. J Surg Case Rep. 2024;2024:rjae175. https:\/\/doi.org\/10.1093\/jscr\/rjae175.","journal-title":"J Surg Case Rep"},{"key":"2102_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1206828","author":"I Uhe","year":"2023","unstructured":"Uhe I, Litchinko A, Liot E. Peptic ulcer disease complicated with choledocho-duodenal fistula and gastro-intestinal bleeding: a case report and review of the literature. Front Surg [Internet] Front. 2023. https:\/\/doi.org\/10.3389\/fsurg.2023.1206828. [cited 2025 Oct 27];10.","journal-title":"Front Surg [Internet] Front"},{"key":"2102_CR192","doi-asserted-by":"publisher","first-page":"e20049","DOI":"10.7759\/cureus.20049","volume":"13","author":"CK Lee","year":"2021","unstructured":"Lee CK, Ramcharan DN, Alaimo KL, Velez V, Risden AE, Klein DH, et al. Cholecystoduodenal fistula evading imaging and endoscopic retrograde cholangiopancreatography: A case report. Cureus. 2021;13:e20049. https:\/\/doi.org\/10.7759\/cureus.20049.","journal-title":"Cureus"},{"key":"2102_CR193","doi-asserted-by":"publisher","unstructured":"Samee A, Shete R, Rana S, Samee M, Zubair Y, Samee A, et al. Gall Stone Ileus and Recurrence: Management Dilemma for the Operating Surgeon. Cureus [Internet] Cureus. 2024. [cited 2025 Oct 27];16. https:\/\/doi.org\/10.7759\/cureus.75577","DOI":"10.7759\/cureus.75577"},{"key":"2102_CR194","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00464-005-0579-6","volume":"20","author":"G Basili","year":"2006","unstructured":"Basili G, Lorenzetti L, Celona G, Biondi G, Preziuso E, Angrisano C, et al. Gallstone ileus in patient with Crohn\u2019s disease. Surg Endosc. 2006;20:703\u20134. https:\/\/doi.org\/10.1007\/s00464-005-0579-6.","journal-title":"Surg Endosc"},{"key":"2102_CR195","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.70793","volume":"13","author":"T Antenucci","year":"2025","unstructured":"Antenucci T, Arena R. A unique case of gallstone ileus in a patient with Crohn\u2019s disease: stone impaction in an ileal adenocarcinoma. Clin Case Rep. 2025;13:e70793. https:\/\/doi.org\/10.1002\/ccr3.70793.","journal-title":"Clin Case Rep"},{"key":"2102_CR196","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.crohns.2008.06.001","volume":"2","author":"R Caprilli","year":"2008","unstructured":"Caprilli R. Why does crohn\u2019s disease usually occur in terminal ileum? J Crohns Colitis. 2008;2:352\u20136. https:\/\/doi.org\/10.1016\/j.crohns.2008.06.001.","journal-title":"J Crohns Colitis"},{"key":"2102_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmgh.2022.09.011","volume":"15","author":"CGC McGregor","year":"2023","unstructured":"McGregor CGC, Tandon R, Simmons A. Pathogenesis of fistulating Crohn\u2019s disease: a review. Cell Mol Gastroenterol Hepatol. 2023;15:1\u201311. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.09.011.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2102_CR198","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","volume":"161","author":"B Barberio","year":"2021","unstructured":"Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterol Elsevier. 2021;161:1865\u201377. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.032.","journal-title":"Gastroenterol Elsevier"},{"key":"2102_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101002","volume":"44","author":"H Crothers","year":"2024","unstructured":"Crothers H, Ferguson J, Quraishi MN, Cooney R, Iqbal TH, Trivedi PJ. Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015\u20132027): a nationwide, population-based study. Lancet Reg Health Eur. 2024;44:101002. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101002.","journal-title":"Lancet Reg Health Eur"},{"key":"2102_CR200","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.3748\/wjg.14.3338","volume":"14","author":"MG Silveira","year":"2008","unstructured":"Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3338\u201349. https:\/\/doi.org\/10.3748\/wjg.14.3338.","journal-title":"World J Gastroenterol"},{"key":"2102_CR201","doi-asserted-by":"publisher","DOI":"10.21037\/tgh-20-266","author":"A Rabiee","year":"2021","unstructured":"Rabiee A, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.21037\/tgh-20-266.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2102_CR202","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.cgh.2013.02.016","volume":"11","author":"S Singh","year":"2013","unstructured":"Singh S, Talwalkar JA. Primary sclerosing Cholangitis \u2013 Diagnosis, prognosis and management. Clin Gastroenterol Hepatol. 2013;11:898\u2013907. https:\/\/doi.org\/10.1016\/j.cgh.2013.02.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2102_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1307297","volume":"15","author":"F Stumme","year":"2024","unstructured":"Stumme F, Steffens N, Steglich B, Mathies F, Nawrocki M, Sabihi M, et al. A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis. Front Immunol. 2024;15:1307297. https:\/\/doi.org\/10.3389\/fimmu.2024.1307297.","journal-title":"Front Immunol"},{"key":"2102_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015431","volume":"24","author":"F Rennebaum","year":"2023","unstructured":"Rennebaum F, Demmig C, Schmidt HH, Vollenberg R, Tepasse P-R, Trebicka J, et al. Elevated liver fibrosis progression in isolated PSC patients and increased malignancy risk in a PSC-IBD cohort: a retrospective study. Int J Mol Sci. 2023;24:15431. https:\/\/doi.org\/10.3390\/ijms242015431.","journal-title":"Int J Mol Sci"},{"key":"2102_CR205","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/liv.13328","volume":"37","author":"K Liu","year":"2017","unstructured":"Liu K, Wang R, Kariyawasam V, Wells M, Strasser SI, McCaughan G, et al. Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. Liver Int. 2017;37:442\u20138. https:\/\/doi.org\/10.1111\/liv.13328.","journal-title":"Liver Int"},{"key":"2102_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11729","volume":"36","author":"M Carbone","year":"2023","unstructured":"Carbone M, Della Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A, et al. Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD)\u2014a European Society of Organ Transplantation (ESOT) consensus statement. Transpl Int. 2023;36:11729. https:\/\/doi.org\/10.3389\/ti.2023.11729.","journal-title":"Transpl Int"},{"key":"2102_CR207","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.13516","volume":"43","author":"J Fevery","year":"2016","unstructured":"Fevery J, Van Steenbergen W, Van Pelt J, Laleman W, Hoffman I, Geboes K, et al. Patients with large-duct primary sclerosing cholangitis and Crohn\u2019s disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther. 2016;43:612\u201320. https:\/\/doi.org\/10.1111\/apt.13516.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38840-8","volume":"14","author":"W Gui","year":"2023","unstructured":"Gui W, Hole MJ, Molinaro A, Edlund K, J\u00f8rgensen KK, Su H, et al. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis. Nat Commun. 2023;14:3304. https:\/\/doi.org\/10.1038\/s41467-023-38840-8.","journal-title":"Nat Commun"},{"key":"2102_CR209","doi-asserted-by":"publisher","unstructured":"Mertz A. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Aog [Internet]. 2019 [cited 2025 Sept 9]; https:\/\/doi.org\/10.20524\/aog.2019.0344","DOI":"10.20524\/aog.2019.0344"},{"key":"2102_CR210","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1136\/gutjnl-2023-330856","volume":"73","author":"T Bedke","year":"2024","unstructured":"Bedke T, Stumme F, Tomczak M, Steglich B, Jia R, Bohmann S, et al. Protective function of sclerosing cholangitis on IBD. Gut. 2024;73:1292\u2013301. https:\/\/doi.org\/10.1136\/gutjnl-2023-330856.","journal-title":"Gut"},{"key":"2102_CR211","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.3748\/wjg.v26.i28.4126","volume":"26","author":"J Aranake-Chrisinger","year":"2020","unstructured":"Aranake-Chrisinger J, Dassopoulos T, Yan Y, Nalbantoglu I. Primary sclerosing cholangitis associated colitis: characterization of clinical, histologic features, and their associations with liver transplantation. World J Gastroenterol. 2020;26:4126\u201339. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4126.","journal-title":"World J Gastroenterol"},{"key":"2102_CR212","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MEG.0000000000002510","volume":"35","author":"A Sayed","year":"2023","unstructured":"Sayed A, Assis DN, Silveira MG, Deng Y, Ciarleglio M, Gaidos JKJ, et al. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2023;35:270\u20134. https:\/\/doi.org\/10.1097\/MEG.0000000000002510.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2102_CR213","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-2006-933561","volume":"26","author":"U Broom\u00e9","year":"2006","unstructured":"Broom\u00e9 U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31\u201341. https:\/\/doi.org\/10.1055\/s-2006-933561.","journal-title":"Semin Liver Dis"},{"key":"2102_CR214","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s41591-023-02372-x","volume":"29","author":"DG Shaw","year":"2023","unstructured":"Shaw DG, Aguirre-Gamboa R, Vieira MC, Gona S, DiNardi N, Wang A, et al. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023;29:1520\u20139. https:\/\/doi.org\/10.1038\/s41591-023-02372-x.","journal-title":"Nat Med"},{"key":"2102_CR215","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77:659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology"},{"key":"2102_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108163","volume":"237","author":"X Liu","year":"2022","unstructured":"Liu X, Wang H, Liu X, Bridle K, Crawford D, Liang X. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: a systematic review and meta-analysis. Pharmacol Ther. 2022;237:108163. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108163.","journal-title":"Pharmacol Ther"},{"key":"2102_CR217","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/liv.13110","volume":"36","author":"EMG de Vries","year":"2016","unstructured":"de Vries EMG, Wang J, Leeflang MMG, Boonstra K, Weersma RK, Beuers UH, et al. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. Liver Int. 2016;36:1867\u201375. https:\/\/doi.org\/10.1111\/liv.13110.","journal-title":"Liver Int"},{"key":"2102_CR218","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jhbp.238","volume":"22","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Hirano K, Tada M, Isayama H, Mizuno S, Arizumi T, et al. Short-term prognostic factors for primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22:486\u201390. https:\/\/doi.org\/10.1002\/jhbp.238.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2102_CR219","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","volume":"18","author":"CRH Hedin","year":"2020","unstructured":"Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, et al. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2020;18:2295-2304.e2. https:\/\/doi.org\/10.1016\/j.cgh.2020.02.014.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2102_CR220","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356\u201378. https:\/\/doi.org\/10.1136\/gutjnl-2018-317993.","journal-title":"Gut"},{"key":"2102_CR221","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000347","volume":"8","author":"A Shah","year":"2024","unstructured":"Shah A, Jones MP, Callaghan G, Fairlie T, Ma X, Culver EL, et al. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: a systematic review and meta-analysis. Hepatol Commun. 2024;8:e0347. https:\/\/doi.org\/10.1097\/HC9.0000000000000347.","journal-title":"Hepatol Commun"},{"key":"2102_CR222","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1080\/14656566.2024.2407022","volume":"25","author":"B Pinnuck","year":"2024","unstructured":"Pinnuck B, Lynch KD. Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis. Expert Opin Pharmacother. 2024;25:1835\u201349. https:\/\/doi.org\/10.1080\/14656566.2024.2407022.","journal-title":"Expert Opin Pharmacother"},{"key":"2102_CR223","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","volume":"18","author":"KD Lynch","year":"2020","unstructured":"Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:179-187.e6. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.013.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2102_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103405","volume":"12","author":"FH Saner","year":"2023","unstructured":"Saner FH, Frey A, St\u00fcben B-O, Hoyer DP, Willuweit K, Daniel M, et al. Transplantation for primary sclerosing cholangitis: outcomes and recurrence. J Clin Med. 2023;12:3405. https:\/\/doi.org\/10.3390\/jcm12103405.","journal-title":"J Clin Med"},{"key":"2102_CR225","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/ajg.2013.163","volume":"108","author":"S Singh","year":"2013","unstructured":"Singh S, Loftus EV, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108:1417\u201325. https:\/\/doi.org\/10.1038\/ajg.2013.163.","journal-title":"Am J Gastroenterol"},{"key":"2102_CR226","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/ibd\/izac132","volume":"29","author":"AR Safarpour","year":"2023","unstructured":"Safarpour AR, Shojaei-Zarghani S, Mehrabi M, Keshtkar AA, Oroojan AA, Sivandzadeh GR. Alterations in the course of inflammatory bowel disease following liver transplantation: a systematic review and meta-analysis. Inflamm Bowel Dis. 2023;29:973\u201385. https:\/\/doi.org\/10.1093\/ibd\/izac132.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR227","doi-asserted-by":"publisher","first-page":"i1599","DOI":"10.1093\/ecco-jcc\/jjae190.1012","volume":"19","author":"J Zhou","year":"2025","unstructured":"Zhou J, Sneek D, Hansen B, den Hoed C, de Jong M, Pan Q, et al. P0838 the clinical outcomes of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. J Crohns Colitis. 2025;19:i1599\u2013600. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1012.","journal-title":"J Crohns Colitis"},{"key":"2102_CR228","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1365-2036.2003.01613.x","volume":"18","author":"EB Haagsma","year":"2003","unstructured":"Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJH, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther. 2003;18:33\u201344. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01613.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR229","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/j.1600-6143.2006.01333.x","volume":"6","author":"RC Verdonk","year":"2006","unstructured":"Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, den Van Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422\u20139. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01333.x.","journal-title":"Am J Transplant"},{"key":"2102_CR230","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cgh.2012.12.027","volume":"11","author":"KK J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen KK, Lindstr\u00f6m L, Cvancarova M, Karlsen TH, Castedal M, Friman S, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:517\u201323. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.027.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2102_CR231","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/MIB.0000000000001105","volume":"23","author":"MR Fattahi","year":"2017","unstructured":"Fattahi MR, Malek-Hosseini SA, Sivandzadeh GR, Safarpour AR, Bagheri Lankarani K, Taghavi AR, et al. <article-title update=\u201cadded\u201d>Clinical course of ulcerative colitis after liver transplantation in patients with concomitant primary sclerosing cholangitis and ulcerative colitis: Inflamm Bowel Dis. 2017;23:1160\u20137. https:\/\/doi.org\/10.1097\/MIB.0000000000001105.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR232","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","volume":"33","author":"D Joshi","year":"2013","unstructured":"Joshi D, Bjarnason I, Belgaumkar A, O\u2019Grady J, Suddle A, Heneghan MA, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int. 2013;33:53\u201361. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02677.x.","journal-title":"Liver Int"},{"key":"2102_CR233","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/ibd\/izx096","volume":"24","author":"MA Mouchli","year":"2018","unstructured":"Mouchli MA, Singh S, Boardman L, Bruining DH, Lightner AL, Rosen CB, et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2018;24:1074\u201381. https:\/\/doi.org\/10.1093\/ibd\/izx096.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR234","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1097\/00042737-200512000-00018","volume":"17","author":"G-T Ho","year":"2005","unstructured":"Ho G-T, Seddon AJ, Therapondos G, Satsangi J, Hayes PC. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol. 2005;17:1379\u201385. https:\/\/doi.org\/10.1097\/00042737-200512000-00018.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2102_CR235","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF01318204","volume":"36","author":"JS Gavaler","year":"1991","unstructured":"Gavaler JS, Delemos B, Belle SH, Heyl AE, Tarter RE, Starzl TE, et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci. 1991;36:321\u20138. https:\/\/doi.org\/10.1007\/BF01318204.","journal-title":"Dig Dis Sci"},{"key":"2102_CR236","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjaa032","volume":"15","author":"L Meunier","year":"2021","unstructured":"Meunier L, Clerc C, Meszaros M. Use of tofacitinib for ulcerative colitis in a liver transplant patient. J Crohns Colitis. 2021;15:695. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa032.","journal-title":"J Crohns Colitis"},{"key":"2102_CR237","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/ajg.2010.33","volume":"105","author":"N El-Nachef","year":"2010","unstructured":"El-Nachef N, Terdiman J, Mahadevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010;105:1210\u20131. https:\/\/doi.org\/10.1038\/ajg.2010.33.","journal-title":"Am J Gastroenterol"},{"key":"2102_CR238","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MEG.0b013e3280116ccc","volume":"19","author":"S Lal","year":"2007","unstructured":"Lal S, Steinhart AH. <article-title update=\u201cadded\u201d>Infliximab for ulcerative colitis following liver transplantation: Eur J Gastroenterol Hepatol. 2007;19:277\u201380. https:\/\/doi.org\/10.1097\/MEG.0b013e3280116ccc.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2102_CR239","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1015408","volume":"2018","author":"R Parekh","year":"2018","unstructured":"Parekh R, Abdulhamid A, Trudeau S, Kaur N. Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. Case Rep Gastroenterol Med. 2018;2018:1015408. https:\/\/doi.org\/10.1155\/2018\/1015408.","journal-title":"Case Rep Gastroenterol Med"},{"key":"2102_CR240","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","volume":"50","author":"R Altwegg","year":"2018","unstructured":"Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, et al. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series. Dig Liver Dis. 2018;50:668\u201374. https:\/\/doi.org\/10.1016\/j.dld.2018.02.014.","journal-title":"Dig Liver Dis"},{"key":"2102_CR241","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2036.2012.05217.x","volume":"36","author":"AB Mohabbat","year":"2012","unstructured":"Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012;36:569\u201374. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05217.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR242","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/lt.24212","volume":"21","author":"P Pavlidis","year":"2015","unstructured":"Pavlidis P, Potts J, Barnabas A, Heaton N, Bjarnason I, Heneghan M, et al. Antitumor necrosis \u03b1 treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation. Liver Transpl. 2015;21:1455\u20136. https:\/\/doi.org\/10.1002\/lt.24212.","journal-title":"Liver Transpl"},{"key":"2102_CR243","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/apt.12256","volume":"37","author":"A Indriolo","year":"2013","unstructured":"Indriolo A, Fagiuoli S, Pasulo L, Fiorino G, Danese S, Ravelli P. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. Aliment Pharmacol Ther. 2013;37:840\u20132. https:\/\/doi.org\/10.1111\/apt.12256.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR244","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/1751-2980.12052","volume":"14","author":"RA Bendez\u00fa Garc\u00eda","year":"2013","unstructured":"Bendez\u00fa Garc\u00eda RA, Rodr\u00edguez Manrique MA, Hern\u00e1ndez Mart\u00ednez A, L\u00e1zaro S\u00e1ez M, Patr\u00f3n Rom\u00e1n GO, Amat Alcaraz S, et al. Biological therapy for crohn\u2019s disease in a liver transplant patient. J Dig Dis. 2013;14:564\u20136. https:\/\/doi.org\/10.1111\/1751-2980.12052.","journal-title":"J Dig Dis"},{"key":"2102_CR245","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.transproceed.2017.09.069","volume":"50","author":"RV Olmedo-Mart\u00edn","year":"2018","unstructured":"Olmedo-Mart\u00edn RV, Amo-Trillo V, Gonz\u00e1lez-Grande R, Tenorio-Gonz\u00e1lez E, S\u00e1nchez-Garc\u00eda O, de la Cruz-Lombardo J, et al. Efficacy and Safety of Anti-TNF-\u03b1 Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series. Transplant Proc. 2018;50:619\u201322. https:\/\/doi.org\/10.1016\/j.transproceed.2017.09.069.","journal-title":"Transplant Proc"},{"key":"2102_CR246","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2036.2012.05141.x","volume":"36","author":"A Sandhu","year":"2012","unstructured":"Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther. 2012;36:159\u201365. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05141.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR247","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ecco-jcc\/jjv109","volume":"9","author":"M Mart\u00ednez-Montiel","year":"2015","unstructured":"Mart\u00ednez-Montiel M, Piedracoba-Cadahia P, G\u00f3mez-G\u00f3mez C, Gonzalo J. Ustekinumab is effective and safe in the treatment of crohn\u2019s disease refractory to anti-TNF\u03b1 in an orthotopic liver transplant patient. J Crohns Colitis. 2015;9:816\u20137. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv109.","journal-title":"J Crohns Colitis"},{"key":"2102_CR248","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1093\/ibd\/izab169","volume":"27","author":"T Shibuya","year":"2021","unstructured":"Shibuya T, Nomura O, Nagahara A. Safety and efficacy of ustekinumab for ulcerative colitis in a liver transplant patient. Inflamm Bowel Dis. 2021;27:e150\u20131. https:\/\/doi.org\/10.1093\/ibd\/izab169.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR249","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/apt.13861","volume":"45","author":"K Hartery","year":"2017","unstructured":"Hartery K, O\u2019Reilly S, Houlihan D, Doherty G, Mulcahy H, Cullen G, et al. Letter: Vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2017;45:376\u20138. https:\/\/doi.org\/10.1111\/apt.13861.","journal-title":"Aliment Pharmacol Ther"},{"key":"2102_CR250","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.1097\/MIB.0000000000000906","volume":"22","author":"TY Lim","year":"2016","unstructured":"Lim TY, Pavlidis P, Gulati S, Pirani T, Samaan M, Chung-Faye G, et al. Vedolizumab in inflammatory bowel disease associated with autoimmune liver disease Pre- and postliver transplantation: A case series. Inflamm Bowel Dis. 2016;22:E39\u201340. https:\/\/doi.org\/10.1097\/MIB.0000000000000906.","journal-title":"Inflamm Bowel Dis"},{"key":"2102_CR251","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/ecco-jcc\/jjv182","volume":"10","author":"M Meszaros","year":"2016","unstructured":"Meszaros M, Pageaux G-P, Altwegg R. Management of ulcerative colitis using vedolizumab after liver transplantation for primary sclerosing cholangitis. J Crohns Colitis. 2016;10:236. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv182.","journal-title":"J Crohns Colitis"},{"key":"2102_CR252","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/lt.24757","volume":"23","author":"AP Wright","year":"2017","unstructured":"Wright AP, Fontana RJ, Stidham RW. Vedolizumab is safe and effective in moderate to severe inflammatory bowel disease following liver transplantation. Liver Transpl. 2017;23:968\u201371. https:\/\/doi.org\/10.1002\/lt.24757.","journal-title":"Liver Transpl"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02102-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02102-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02102-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:35:46Z","timestamp":1781645746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02102-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":252,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2102"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02102-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"219"}}